HealthLumen

What HealthLumen does

HealthLumen is a London-based precision epidemiology company founded in May 2019 by Dr Simon Lande (CEO) and Dr Laura Webber (COO), both former members of the UK Health Forum. The company was established through the acquisition of a microsimulation platform with a 12-year track record of modelling non-communicable diseases, originally developed within the UK Health Forum. HealthLumen's core technology is a patient-level microsimulation platform that simulates individual virtual populations over time, modelling disease emergence, progression, and outcomes at a patient level, and aggregating these into population-level burden of disease estimates. The platform accounts for heterogeneity in baseline risk, treatment uptake, adherence, and response, and supports counterfactual scenario analysis. A second proprietary capability — genetic database analysis, commercialised as the AlleleAtlas tool — mines large-scale genetic databases (gnomAD, UK Biobank, Genomics England's 100K Genomes, All of Us) to estimate variant prevalence, stratify by ancestry, and determine penetrance for rare genetic diseases.

HealthLumen generates revenue exclusively through commissioned, project-based consulting engagements. Clients include pharmaceutical and biotech companies (AstraZeneca, Bristol-Myers Squibb, Gilead), biotech investors, and public sector organisations (Cancer Research UK, British Heart Foundation, EASL, Movember, World Bank, Public Health England, NHS). The flagship commercial programme is INSIDE CKD, a multi-year strategic collaboration with AstraZeneca projecting the global clinical and economic burden of chronic kidney disease. The go-to-market motion is consultative B2B, driven by thought leadership content, peer-reviewed publications in major journals, and presence at international congresses in nephrology, diabetes, hepatology, and health economics. Pricing is bespoke and not publicly disclosed. The company operates from a serviced office in London and serves clients across 80+ countries covering 25+ diseases.

Name

HealthLumen

Legal name

HealthLumen

Website

https://healthlumen.com

Company type

Private

Founded year

2019

Operating status

Operating

Headcount range

11–50 employees

Short description

HealthLumen is a London-based precision epidemiology company that applies a proprietary 12-year-old microsimulation platform and genetic database analysis (AlleleAtlas) to forecast disease burden for pharmaceutical, biotech, and public sector clients across 80+ countries.

Ownership category

akta.pro rank

Product category

Health Economics Consulting

NAICS

Health Care and Social Assistance (62)

SIC

Services-Health Services (8000)

akta.pro primary industry

Data Linkage, Registries & Longitudinal Cohort Surveillance (HLAJANAM)

Keywords

• Epidemiological modeling services
• Precision epidemiology consulting
• Microsimulation disease modeling
• Rare disease analytics
• Health economic forecasting

Headquarters

HQ city

London

HQ country

United Kingdom

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales

Revenue model

1. Consulting and Modelling Services: HealthLumen generates revenue through commissioned consulting projects where they apply their epidemiological modelling capabilities. Clients (pharmaceutical companies, biotech firms, public sector organisations) engage HealthLumen to model specific disease burdens, evaluate interventions, project future health economic outcomes, and generate evidence for policy change or market access. Projects are typically bespoke, scoped per engagement.

Go-to-market motion2 records

Distribution channels1 record

Marketing channels6 records

Core offering

HealthLumen provides precision epidemiology services through a proprietary microsimulation modeling platform and genetic database analysis methodology. The company quantifies the current and future burden of non-communicable diseases and rare genetic diseases, generating evidence to support pharmaceutical R&D, clinical trial design, market access, and public health policy decisions. Its named offerings include AlleleAtlas (a genetic database analysis tool) and Inside CKD (a CKD research program developed with AstraZeneca).

Product overview

HealthLumen offers a precision epidemiology platform centered on microsimulation modeling combined with genetic database analysis. Their core product is the microsimulation modeling platform, which simulates individual-level disease progression to generate population-level burden of disease estimates. Key offerings include AlleleAtlas (a genetic database analysis tool) and the Inside CKD research program developed with AstraZeneca. The platform supports the entire drug development lifecycle from R&D through market access, serving pharmaceutical companies, biotech firms, and public sector organizations with evidence generation for strategic planning, clinical trial design, and health economic evaluations.

Differentiator

Problem solved

Functional benefit

Products and services

• AlleleAtlas A genetic database analysis tool that enables mining of large-scale genetic databases to identify pathogenic variants, stratify patient populations by ancestry, and estimate disease prevalence for rare genetic diseases. It supports pharmaceutical, biotech, and public sector clients in understanding rare genetic disease patient populations.
• Microsimulation Modeling Platform A patient-level microsimulation platform that simulates individual virtual populations to model disease emergence, progression, and outcomes over time. It accounts for heterogeneity in baseline risk, disease trajectories, treatment responses, and real-world variation in care pathways, and is the core platform underpinning HealthLumen's consulting and research engagements.
• Inside CKD A comprehensive research program developed with AstraZeneca that projects the global clinical and economic burden of chronic kidney disease (CKD), including anemia of CKD, across multiple countries from 2021 to 2026. It supports evidence-based policy making and Market Access workstreams in CKD and is presented at major congresses including ERA-EDTA and ADA.
• Genetic Database Analysis Service A proprietary methodology for analyzing large genetic databases (gnomAD, UK Biobank, Genomics England's 100K Genomes, All of Us) to estimate disease prevalence, identify at-risk populations by ancestry, and support drug development decisions for rare genetic diseases. Delivered as a bespoke service to pharmaceutical, biotech, and public sector clients.

Quantifiable outcome

• If all preventable cases of five conditions (CHD, COPD, lung cancer, colorectal cancer, suicide) had been avoided in Canadian men in 2023, Canada could have saved $12.4 billion CAD.
• +5 more outcomes

Named customers11 records

Segments3 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability5 records

Feature4 records

Partnerships

Six partnerships are on record, tiered core, key and minor.

• Imperial College Business School - Centre for Health Economics and Policy InnovationcoreStrategic or Co-development PartnerHealthLumen collaborates closely with Imperial College Business School's Centre for Health Economics and Policy Innovation. This partnership likely involves academic collaboration on research methodologies, student talent, and joint publications in health economics and policy.
• The Royal Society for Public Health (RSPH)coreStrategic or Co-development PartnerHealthLumen's charity partner, continuing from their roots at the UK Health Forum. Partnership focuses on supporting improvements in population health through better decision making. HealthLumen COO co-authored guest blog for RSPH on role of computer modelling in post-COVID decision making.
• AstraZenecacoreStrategic or Co-development PartnerStrategic collaboration on the INSIDE CKD programme - part of AstraZeneca's major strategic initiative dedicated to changing the future for CKD patients. HealthLumen provides microsimulation modelling to project global clinical and economic burden of chronic kidney disease. Multiple joint publications and congress presentations from this collaboration.
• UK Health ForumcoreOthersHealthLumen acquired the microsimulation platform and core team from UK Health Forum in 2019. The platform came with 12-year track record of modelling NCDs. This acquisition was foundational to establishing HealthLumen as a company.
• EASL (European Association for the Study of the Liver)keyStrategic or Co-development PartnerCommissioned by EASL for HepaHealth I and II projects. HealthLumen created epidemiological and policy intervention databases for liver disease, synthesising data across 35 European countries. Supported by unrestricted education grants from Bristol-Myers Squibb and Gilead.
• One Avenue Limited / Dawson HouseminorOthersServiced office provider for HealthLumen's London headquarters at Dawson House. Provides fully serviced office space including IT, meeting rooms, reception facilities, and other office services.

Scale indicators3 records

Recent moves7 records

Expansion highlights5 records

Direct peers

• Lumanity: HEOR, market access, and evidence synthesis consultancy formed by combining LSC and Peloton Advantage. Competes head-to-head with HealthLumen on burden-of-disease studies, economic modelling, and value communication for pharma and biotech clients.
• PHMR: Health economics and outcomes research consultancy providing burden-of-disease, real-world evidence, and HEOR studies to pharma and public-sector clients. Highly comparable on service offering and customer base, including public health and policy use cases.
• Genesis Research: Specialist health economics, HEOR, and real-world evidence consultancy supporting pharma and biotech across R&D, market access, and post-launch. Closely comparable to HealthLumen on epidemiological modelling and reimbursement evidence generation for life sciences.
• Cytel: Statistical, Bayesian, and microsimulation modelling firm with strong pharma/biotech and clinical trial focus. Highly comparable to HealthLumen's microsimulation methodology offering, including patient-level simulation and health economic evaluation for life sciences.
• Evidera (Thermo Fisher PPD): Established HEOR, real-world evidence, and disease-modelling consultancy serving pharma/biotech across the drug development lifecycle. Directly comparable to HealthLumen on value proposition (burden of disease, health economic modelling, market access evidence) but at materially larger scale and with broader geographic delivery.
• BresMed: Independent health economics and outcomes research consultancy serving pharma, biotech, and medtech. Directly comparable on disease burden modelling, HTA submissions, and economic evaluation projects, particularly within EU markets where HealthLumen also operates.

Others

• Trinity Life Sciences: Life sciences strategy and insights consultancy serving pharma/biotech with commercial, R&D, and market access advisory. Adjacent peer rather than direct competitor — overlaps with HealthLumen on commercial evidence use cases but operates from a strategic-consulting rather than modelling methodology angle.
• Charles River Associates (CRA Life Sciences): Global consulting firm with a Life Sciences practice providing economic and strategic analysis to pharma and biotech. Comparable to HealthLumen when engagements intersect on health economics and policy impact, but positioned as broad strategy/advisory rather than epidemiology consultancy.

Broad incumbents

• IQVIA: Largest global CRO and real-world evidence provider, with extensive HEOR, epidemiology, and disease-modelling capabilities inside its Real World Solutions practice. Competes with HealthLumen on RWE and burden-of-disease engagements for top-20 pharma, but as part of a much wider services portfolio.
• Clarivate (Decision Resources Group): Global intelligence and analytics provider whose DRG and Cortellis units deliver disease landscape, epidemiology, and market access analytics. Competes with HealthLumen on epidemiology and disease-burden deliverables used by pharma portfolio and brand teams, but at much broader scope.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/healthlumen
• Xx.com/healthlumen

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about HealthLumen